March 19th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Daneng Li, MD, discussed the available therapy options for a patient with advanced hepatocellular carcinoma.
Physicians Discuss Their Impressions of Recent IO/TKI Trials for HCCFebruary 6th 2023
During a Targeted Oncology case-based roundtable event, Amit Singal, MD, and participants discussed the significance of LEAP-002 and other trials investigating immunotherapy plus tyrosine kinase inhibitor therapy in patients with hepatocellular carcinoma.
SBRT Plus Sorafenib Improves Survival in Locally Advanced HCCFebruary 1st 2023
In an interview with Targeted Oncology, Laura Dawson, MD, FRCPC, discussed the results of the phase 3 NRG/RTOG 1112 study of SBRT followed by sorafenib compared with sorafenib alone in locally advanced hepatocellular carcinoma.
Sorafenib in Combination with SBRT Extends Survival in Locally Advanced HCCJanuary 21st 2023
The phase 3 NRG/RTOG 1112 adds to the body of evidence for the role of external beam radiation, bringing SBRT to the armamentarium of treatment for patients with locally advanced hepatocelluar carcinoma, according to Laura Dawson, MD, FRCPC.
Early Trial Results Show Promise for Combination of Lenvatinib, TACE, and Microwave Ablation in HCCJanuary 20th 2023
Results from the phase 2 Talem trial, presented at the 2023 Gastrointestinal Cancers Symposium, showed the promising signs of efficacy, anti-tumor activity, and tolerable adverse events when combining blank-microsphere transarterial chemoembolization with lenvatinib and sequential microwave ablation for patients with HCC.
No Affect Seen With Anti-Drug Antibodies on Durvalumab Alone or With Tremelimumab in HCCJanuary 20th 2023
Anti-drug antibodies did not seem to affect how well the STRIDE regimen of durvalumab and tremelimumab or durvalumab alone worked in patients with unresectable hepatocellular carcinoma.
Addition of Pembrolizumab to Lenvatinib for HCC Elicits Similar Scores in LEAP-002January 20th 2023
Data from the health-related quality of life analysis of the LEAP-002 study showed similar scores with the addition of pembrolizumab to lenvatinib vs placebo plus lenvatinib in patients with hepatocellular carcinoma.
Lenvatinib Elicits Survival Benefit After Progression on Immunotherapy in HCCJanuary 20th 2023
Patients with advanced hepatocellular carcinoma who were treated with lenvatinib following progression on immunotherapy had a median overall survival of 12.8 months and progression-free survival of 3.7 months.
Adjuvant Atezolizumab Plus Bevacizumab Improve RFS in Early-Stage Hepatocellular CarcinomaJanuary 19th 2023
In IMbrave050, the risk of disease recurrence or death was decreased with adjuvant atezolizumab and bevacizumab compared with active surveillance in patients with early-stage hepatocellular carcinoma.
Significance of Lenvatinib/Pembrolizumab Vs Lenvatinib Outcomes in HCCJanuary 16th 2023
During a Targeted Oncology case-based roundtable event, Amit Singal, MD, discussed the data from the LEAP-002 trial of lenvatinib/pembrolizumab vs lenvatinib in patients with hepatocellular carcinoma.
Roundtable Discussion: Treatment Goals for HCC and Tolerability of Frontline RegimensDecember 27th 2022
During a Targeted Oncology case-based roundtable event, Richard S. Finn, MD, discussed the case of a patient with a 4.5-cm Liver Imaging Reporting and Data System category 5 (LR-5) hepatic mass, Crohn disease, and cirrhosis.
Discussing the LEAP-002 Trial of Lenvatinib Plus Pembrolizumab in HCCNovember 9th 2022
During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, MBA, discusses with participants the unexpected results of the LEAP-002 trial of lenvatinib plus pembrolizumab versus pembrolizumab alone for patients with hepatocellular carcinoma. This is the second of 2 articles based on this event.
Health Derailed in Houston After Authorities Confirm Liver Cancer ClusterOctober 31st 2022
Considering the higher-than-average rate of liver cancer in Texas as a whole, it was unexpected that the Kashmere Gardens neighborhood cluster would be linked to environmental issues. Texas Department of State Health Services and the City of Houston confirm the cluster exists and is caused by toxins polluted into the soil by The Union Pacific Railroad.
Interpreting Results From New and Previous Trials of Lenvatinib in HCCOctober 26th 2022
During a live virtual event, Ghassan K. Abou-Alfa, MD, discussed the results of the REFLECT trial of lenvatinib versus sorafenib and the LEAP-002 trial of lenvatinib/pembrolizumab versus lenvatinib in patients with hepatocellular carcinoma.
Liver Cancer Awareness Month: A Decade of Progress and Hope in Hepatocellular CarcinomaOctober 26th 2022
Mahvish Muzaffar, MD, and Nasreen Vohra, MD, from the Brody School of Medicine/East Carolina University, discuss the past decade of progress in treatment for patients with hepatocellular carcinoma.
Regorafenib Then Nivolumab Sequence Is Tolerable After First-Line HCC TreatmentOctober 14th 2022
Data presented during the 2022 International Liver Cancer Association Conference showed that less than one-third of patients with hepatocellular carcinoma who received regorafenib followed by nivolumab experienced grade 3 or 4 treatment-related adverse events.
Gene Expression Signatures Are Analyzed for Biomarkers of Response in HCCOctober 14th 2022
The phase 1b Study 116/KEYNOTE-524 trial of lenvatinib and pembrolizumab revealed the RAS gene signature to possibly be associated with progression-free survival in unresectable hepatocellular carcinoma.